Court: United States District Court for the District of Massachusetts

Result: $340 Million settlement

WBE and co-counsel recovered $340 million for a certified class of direct purchasers to resolve claims that Ranbaxy allegedly manipulated the U.S. Food and Drug Administration’s generic drug approval process to block competitors from entering the market, forcing purchasers to pay supracompetitive prices.